Hyperphenylalaninemia Hpa — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for hyperphenylalaninemia hpa . 8 active patents protecting 1 drugs from 1+ originators. First major cliff: 2038. Daily refresh.

1
Approved drugs
8
Active US patents
75/100
Avg vulnerability
—
Annual revenue covered

Originators in Hyperphenylalaninemia Hpa

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Ptc Therap 8 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating hyperphenylalaninemia hpa . Each bar = one year. Y-axis scaled to peak year (6 patents).

6
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Sephience
SEPIAPTERIN
 Ptc Therap 8 75 — 2038-04-16

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11072614 Sephience method of use 75 2038-04-16
11072614 Sephience method of use 75 2038-04-16
12213982 Sephience method of use 75 2038-09-04
11752154 Sephience method of use 75 2038-09-04
12213982 Sephience method of use 75 2038-09-04
11752154 Sephience method of use 75 2038-09-04
12257252 Sephience method of use 75 2042-03-06
12257252 Sephience method of use 75 2042-03-06

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12257252 Sephience method of use 75 2042-03-06
12257252 Sephience method of use 75 2042-03-06
11752154 Sephience method of use 75 2038-09-04
12213982 Sephience method of use 75 2038-09-04
11752154 Sephience method of use 75 2038-09-04
12213982 Sephience method of use 75 2038-09-04
11072614 Sephience method of use 75 2038-04-16
11072614 Sephience method of use 75 2038-04-16

Related